You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 19, 2024

Polidocanol - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic drug sources for polidocanol and what is the scope of patent protection?

Polidocanol is the generic ingredient in two branded drugs marketed by Chemisch Fbrk Krsslr and Provensis, and is included in two NDAs. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Polidocanol has ninety-seven patent family members in thirty countries.

Two suppliers are listed for this compound.

Summary for polidocanol
International Patents:97
US Patents:4
Tradenames:2
Applicants:2
NDAs:2
Finished Product Suppliers / Packagers: 2
Raw Ingredient (Bulk) Api Vendors: 76
Clinical Trials: 24
Patent Applications: 4,557
Formulation / Manufacturing:see details
What excipients (inactive ingredients) are in polidocanol?polidocanol excipients list
DailyMed Link:polidocanol at DailyMed
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for polidocanol
Generic Entry Date for polidocanol*:
Constraining patent/regulatory exclusivity:
Dosage:
SOLUTION;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for polidocanol

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Assiut UniversityPhase 4
Hospital de Clínicas Dr. Manuel QuintelaPhase 4
Centro Cardiovascular UniversitarioPhase 4

See all polidocanol clinical trials

Pharmacology for polidocanol
Drug ClassSclerosing Agent
Mechanism of ActionSclerosing Activity
Physiological EffectVascular Sclerosing Activity

US Patents and Regulatory Information for polidocanol

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Chemisch Fbrk Krsslr ASCLERA polidocanol SOLUTION;INTRAVENOUS 021201-002 Mar 30, 2010 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Chemisch Fbrk Krsslr ASCLERA polidocanol SOLUTION;INTRAVENOUS 021201-001 Mar 30, 2010 RX Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Provensis VARITHENA polidocanol SOLUTION;INTRAVENOUS 205098-001 Nov 25, 2013 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Provensis VARITHENA polidocanol SOLUTION;INTRAVENOUS 205098-001 Nov 25, 2013 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for polidocanol

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Provensis VARITHENA polidocanol SOLUTION;INTRAVENOUS 205098-001 Nov 25, 2013 ⤷  Try a Trial ⤷  Try a Trial
Provensis VARITHENA polidocanol SOLUTION;INTRAVENOUS 205098-001 Nov 25, 2013 ⤷  Try a Trial ⤷  Try a Trial
Provensis VARITHENA polidocanol SOLUTION;INTRAVENOUS 205098-001 Nov 25, 2013 ⤷  Try a Trial ⤷  Try a Trial
Provensis VARITHENA polidocanol SOLUTION;INTRAVENOUS 205098-001 Nov 25, 2013 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.